T1476

Pramipexole (SND 919) is a selective dopamine receptor agonist used in the therapy of Parkinson disease. Pramipexole therapy is associated with a low rate of transient serum enzyme elevations during treatment but has not been implicated in cases of clinically apparent acute liver injury.

BP 897 is a potent and selective agonist of dopamine D3 receptor and it is a weak dopamine D2 receptor antagonist, with Kis of 0.92 nM and 61 nM for D3 and D2 receptors. Which shows low affinities at D1 and D4 receptors (Kis, 3 and 0.3 μM, respectively).

Boc-PEG2-sulfonic acid is a PEG-based linker for PROTACs, joining two essential ligands and enabling selective protein degradation through the ubiquitin-proteasome system within cells.

Boc-PEG4-phosphonic acid ethyl ester is a polyethylene glycol (PEG) derived linker compound used in the synthesis of PROteolysis TArgeting Chimeras (PROTACs) [1].

Boc-PEG4-sulfonic acid is a PEG-based linker for PROTACs, facilitating the connection between two essential ligands necessary for PROTAC molecule formation, thereby enabling selective protein degradation through the ubiquitin-proteasome system within cells.

BoNT-IN-1 is a potent inhibitor of Botulinum neurotoxin A light chain (BoNTA LC) with an IC50 of 0.9 µM.

BOS-172722 is an inhibitor of the monopolar spindle 1 (MPS1) checkpoint with an IC50 of 2 nM.

BPH-715 inhibits the liver-stage growth of P. falciparum with an IC50 of 10 μM for P. falciparum exoerythrocytic forms in HepG2 cells.

Br-PEG3-C2-Boc is a PEG-based linker for PROTACs, facilitating the conjugation of two essential ligands crucial for PROTAC molecule formation, and enabling selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Br-PEG3-CH2COOH is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Pramipexole dihydrochloride could be used to treat Parkinson disease.

DC-S100 is a selective histone methyltransferase SET7 inhibitor.